Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on February 2, 2009, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedules I and II: Drug
ScheduleCathinone (1235)
IMethcathinone (1237)
IN-Ethylamphetamine (1475)
IFenethylline (1503)
IMethaqualone (2565)
IGamma Hydroxybutyric Acid (2010)
ILysergic acid diethylamide (7315)
I2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
IMarihuana (7360)
ITetrahydrocannabinols (7370)
IMescaline (7381)
I3,4,5-Trimethoxyamphetamine (7390)
I4-Bromo-2,5-dimethoxyamphetamine (7391)
I4-Bromo-2,5-dimethoxyphenethylamine (7392)
I4-Methyl-2,5-dimethoxyamphetamine (7395)
I2,5-Dimethoxyamphetamine (7396)
I2,5-Dimethoxy-4-ethylamphetamine (7399)
I( print page 16235)3,4-Methylenedioxyamphetamine (7400)
I3,4-Methylenedioxy-N-ethylamphetamine (7404)
I3,4-Methylenedioxymethamphetamine (7405)
I4-Methoxyamphetamine (7411)
IDimethyltryptamine (7435)
IPsilocybin (7437)
IPsilocyn (7438)
IN-Benzylpiperazine (7493)
IAcetyldihydrocodeine (9051)
IDihydromorphine (9145)
IHeroin (9200)
INormorphine (9313)
IPholcodine (9314)
ITilidine (9750)
I3-Methylfentanyl (9813)
IAmphetamine (1100)
IIMethamphetamine (1105)
IIMethylphenidate (1724)
IIAmobarbital (2125)
IIPentobarbital (2270)
IISecobarbital (2315)
IIPhencyclidine (7471)
IIPhenylacetone (8501)
IICocaine (9041)
IICodeine (9050)
IIDihydrocodeine (9120)
IIOxycodone (9143)
IIHydromorphone (9150)
IIBenzoylecgonine (9180)
IIEthylmorphine (9190)
IIHydrocodone (9193)
IILevorphanol (9220)
IIMeperidine (9230)
IIMethadone (9250)
IIDextropropoxyphene, bulk (non-dosage forms) (9273)
IIMorphine (9300)
IIThebaine (9333)
IIOxymorphone (9652)
IIAlfentanil (9737)
IISufentanil (9740)
IIFentanyl (9801)
II
 The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections being sent via regular or express mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than May 11, 2009. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the 
                    **Federal Register**
                     on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: April 1, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. E9-8088 Filed 4-8-09; 8:45 am] BILLING CODE 4410-09-P